ElectroCore, Inc. Announces Additions to Board of Directors in Connection with Recently Completed Initial Public Offering
July 10, 2018 at 08:00 am EDT
Share
electroCore Inc. announced the appointment of Carrie S. Cox as Chairman of its Board of Directors, and Michael G. Atieh and Stephen L. Ondra, M.D. as recent additions to the Board. Ms. Cox most recently served as Chief Executive Officer of Humacyte Inc. and previously as President, Global Pharmaceuticals, at Schering-Plough Corporation from 2003 until its merger with Merck & Co. Inc. in November 2009. Mr. Atieh spent the majority of his career in the biotechnology and pharmaceutical industries, including 20 years at Merck & Co. Inc. Prior to his retirement in 2016, Mr. Atieh was Executive Vice President, Chief Financial and Business Officer at Ophthotech Inc. Dr. Ondra is Chief Executive Officer of North Star Healthcare Consulting.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company. It provides non-invasive vagus nerve stimulation (nVNS) technology platform. The Companyâs product categories include Handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headache, and Handheld, personal use consumer products utilizing nVNS technology to promote general wellness and human performance. Its products include gammaCore, Truvaga and TAC-STIM. Its gammaCore Sapphire, is a prescription medical device that is used for a variety of primary headache conditions. Its Truvaga is a personal use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com. The Companyâs TAC-STIM product is not a medical device and is not intended to diagnose, cure, mitigate, prevent, or treat a disease or condition.
ELECTROCORE, INC. 
